Literature DB >> 2677830

Familial X-linked myalgia and cramps: a nonprogressive myopathy associated with a deletion in the dystrophin gene.

S M Gospe1, R P Lazaro, N S Lava, P M Grootscholten, M O Scott, K H Fischbeck.   

Abstract

We report a family with an X-linked recessive disorder characterized by muscle cramps and myalgia. Nine affected male family members had high resting serum levels of creatine kinase, and well-developed musculature with calf hypertrophy but no evidence of muscular weakness. Symptoms began in childhood and did not progress. Electromyographic findings were consistent with myopathy while muscle biopsies showed nonspecific myopathic changes without evidence of storage of glycogen or lipid. Analysis of DNA revealed a deletion in the 1st third of the dystrophin gene. Western blot analysis revealed that dystrophin was smaller than that in normal samples, with no reduction in the amount of the protein present. This disorder represents a new clinical phenotype associated with a deletion in the dystrophin gene. This deletion affects a portion of the dystrophin molecule that clinically does not appear to significantly alter its function. Other patients with deletions in this region may have truncated dystrophin without clinical signs of progressive muscle disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2677830     DOI: 10.1212/wnl.39.10.1277

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

Review 1.  Molecular biology of neurological diseases.

Authors:  W J Cumming
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

Review 2.  Recent advances in understanding muscular dystrophy.

Authors:  K M Bushby
Journal:  Arch Dis Child       Date:  1992-10       Impact factor: 3.791

Review 3.  Genetic and clinical correlations of Xp21 muscular dystrophy.

Authors:  K M Bushby
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

4.  Phenotypic heterogeneity and the single gene.

Authors:  G K Suthers; K E Davies
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

5.  An intact cysteine-rich domain is required for dystrophin function.

Authors:  R D Bies; C T Caskey; R Fenwick
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

6.  Reproductive fitness and frequency of new mutations in Becker muscular dystrophy: implications for genetic risk estimates.

Authors:  M R Passos-Bueno; M Zatz
Journal:  J Med Genet       Date:  1991-04       Impact factor: 6.318

Review 7.  Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases.

Authors:  Craig M McDonald
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

8.  Abnormal dystrophin expression in patients with limb girdle syndromes.

Authors:  S Beyenburg; S Zierz; K Arahata; R R Mundegar; W Friedl; F Jerusalem
Journal:  J Neurol       Date:  1994-02       Impact factor: 4.849

9.  Mild deficiency of dystrophin-associated proteins in Becker muscular dystrophy patients having in-frame deletions in the rod domain of dystrophin.

Authors:  K Matsumura; I Nonaka; F M Tomé; K Arahata; H Collin; F Leturcq; D Récan; J C Kaplan; M Fardeau; K P Campbell
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

10.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history.

Authors:  K M Bushby; D Gardner-Medwin
Journal:  J Neurol       Date:  1993-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.